On March 23, 2020, Hang Seng Index Co., Ltd. launched the Hang Seng Stock Connect Biotech 50 Index. CMS (867.HK) has been included.
The Hang Seng Stock Connect Biotech 50 Index tracks the overall performance of the 50 largest biotech companies in terms of market capitalisation that are listed in Hong Kong or Mainland China and are eligible for trading through the Stock Connect Scheme. Companies are considered to be biotech companies for the purposes of the index if they are classified as ‘Biotechnology’, ‘Pharmaceuticals’ or ‘Medical Devices’ under the Hang Seng Industry Classification System. This new cross-market index provides a tradable benchmark for product issuers who are interested in the fast-growing field of biotechnology.
In the future, CMS will continue to accelerate the strategic layout of innovative products. In the future, CMS will continue to accelerate the strategic layout of innovative products, through seeking and strengthening long-term cooperation with the world’s leading pharmaceutical companies, which will inject advanced innovative technologies and rich innovative product clusters into the Chinese pharmaceutical market. At the same time, by continuously optimizing and upgrading the existing academic network to create a professional, compliant and efficient academic promotion system, CMS Group will continue to release long-term development driving forces for the Group’s innovative product clusters and high-quality brand medicines.